AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16048220 — intervention group
Group type: COMPARATOR
Intervention: DuoDERM E dressing
Number of subjects: 91
Study 12351482 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1
Number of subjects: 239
Study 9842243 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 31
Study 9842243 — intervention group
Group type: COMPARATOR
Intervention: Amikacin/metronidazole combination
Number of subjects: 31
Study 8018396 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 60 mg suppositories every 4 h
Number of subjects: 136
Study 8018396 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine 25 mg suppositories every 4 h
Number of subjects: 136
Study 2904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G and sulphadiazine for 5 days postoperatively
Number of subjects: 3180
Study 2904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for 5 days postoperatively
Number of subjects: 3180
Study 2904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin and sulphadiazine for 5 days postoperatively
Number of subjects: 3180
Study 2904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin for 5 days postoperatively
Number of subjects: 3180
Study 2904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for 5 days preoperatively
Number of subjects: 3180
Study 2904464 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled studies with no specific intervention
Number of subjects: 3180
Study 28816881 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 60
Study 28816881 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberscope
Number of subjects: 60
Study 27530232 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (intravenous)
Number of subjects: 30
Study 25288038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hyperoxia (InHO) for 4 hours daily for 2 weeks
Number of subjects: 62
Study 25288038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hyperoxia (InHO)
Number of subjects: 62
Study 25288038 — intervention group
Group type: COMPARATOR
Intervention: Control group (breathing air via non-rebreathing reservoir mask)
Number of subjects: 62
Study 23960180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance for 8 months, once every 2 months for a total of four doses
Number of subjects: 202
Study 23960180 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 202
Study 21968665 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO)
Number of subjects: 20
Study 21968665 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (ONA)
Number of subjects: 20
Study 18192898 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg NRT transdermal patch for 8 weeks
Number of subjects: 0
Study 18192898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (NRT)
Number of subjects: 0
Study 18192898 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT transdermal patch
Number of subjects: 0
Study 16582058 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief therapy
Number of subjects: 702
Study 16582058 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 702
Study 16582058 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 702
Study 12642264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy shock wave treatment (3 applications of 2100 impulses)
Number of subjects: 45
Study 12642264 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 45
Study 10955372 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.30 mg/kg IV)
Number of subjects: 36
Study 10955372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (0.15 mg/kg IV)
Number of subjects: 36
Study 10955372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8805958 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking program
Number of subjects: 21
Study 1624927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg)
Number of subjects: 20
Study 1624927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg)
Number of subjects: 20
Study 1624927 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (800 mg) and 400 mg
Number of subjects: 20
Study 1624927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 20
Study 6526589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sensitivity feedback
Number of subjects: 90
Study 6526589 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity feedback
Number of subjects: 90
Study 6526589 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 90
Study 29877227 — intervention group
Group type: EXPERIMENTAL
Intervention: Paprika xanthophylls (9 mg) administered daily for 5 weeks
Number of subjects: 46
Study 29877227 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for 5 weeks
Number of subjects: 46
Study 26523330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg triptorelin
Number of subjects: 165
Study 26523330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg triptorelin
Number of subjects: 165
Study 26523330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg triptorelin
Number of subjects: 165
Study 23668822 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-discrepancy monitoring (SDM) after recalling a positive memory
Number of subjects: 0
Study 23668822 — intervention group
Group type: COMPARATOR
Intervention: Control condition (observing feelings after recalling a positive memory)
Number of subjects: 0
Study 23539724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg ACTH(1-24) intravenous stimulation test
Number of subjects: 81
Study 23539724 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg ACTH(1-24) intramuscular stimulation test
Number of subjects: 81
Study 23539724 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cortisol measurement
Number of subjects: 81
Study 23539724 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cortisol measurement by immunoassay and LCMS
Number of subjects: 81
Study 20065185 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R)
Number of subjects: 3
Study 20065185 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg/d plus placebo (A + P)
Number of subjects: 3
Study 20065185 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (A) alone
Number of subjects: 3
Study 20065185 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R) in high-risk group
Number of subjects: 3
Study 18719507 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 62
Study 18719507 — intervention group
Group type: COMPARATOR
Intervention: Metallic stents
Number of subjects: 62
Study 17080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 206
Study 17080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 206
Study 15570651 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol/APAP (tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 338
Study 15570651 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 338
Study 11305854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 42
Study 11305854 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 42
Study 9230863 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine 5 minutes before incision)
Number of subjects: 112
Study 9230863 — intervention group
Group type: COMPARATOR
Intervention: Postincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine immediately after approximation of the fascia)
Number of subjects: 112
Study 10132454 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus guidelines agreed between GPs and specialists
Number of subjects: 179
Study 10132454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guidelines)
Number of subjects: 179
Study 3028458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ramipril
Number of subjects: 6
Study 3028458 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study 29708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (α1-agonist) during exercise trials
Number of subjects: 16
Study 29708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (α2-agonist) during exercise trials
Number of subjects: 16
Study 29708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting and high flow trials with α1 and α2 agonists
Number of subjects: 16
Study 27779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over M1
Number of subjects: 0
Study 27779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over DLPFC
Number of subjects: 0
Study 27779192 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over M1
Number of subjects: 0
Study 27779192 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over DLPFC
Number of subjects: 0
Study 27779192 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 0
Study 25703911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 59
Study 25703911 — intervention group
Group type: EXPERIMENTAL
Intervention: INB (iliohypogastric nerve block)
Number of subjects: 59
Study 25703911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal prilocaine‐lidocaine cream application
Number of subjects: 59
Study 25703911 — intervention group
Group type: EXPERIMENTAL
Intervention: INB + intrarectal prilocaine‐lidocaine cream application (combined group)
Number of subjects: 59
Study 24142084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-based thought record (TBTR)
Number of subjects: 0
Study 24142084 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive therapy (CCT)
Number of subjects: 0
Study 20606084 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg/d orally for 7 consecutive days (IM-positive group)
Number of subjects: 94
Study 20606084 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (IM-negative group)
Number of subjects: 94
Study 18379217 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of blood flow (RBF) group: external compressive force of 200 mm Hg for 5 min followed by 3 min of rest, repeated five times in a single session, two sessions per day for 14 days
Number of subjects: 15
Study 18379217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training (IMT) group: 20 exercises of 5-s isometric contraction of knee extensor, flexor, and ankle plantar flexor muscles, twice a day for 2 weeks
Number of subjects: 15
Study 18379217 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group: no intervention
Number of subjects: 15
Study 16761158 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (lornoxicam)
Number of subjects: 122
Study 16761158 — intervention group
Group type: COMPARATOR
Intervention: Coxib (rofecoxib)
Number of subjects: 122
Study 14648269 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-thigh pneumatic compression
Number of subjects: 121
Study 14648269 — intervention group
Group type: COMPARATOR
Intervention: Plantar compression
Number of subjects: 121
Study 10072029 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.08 mg/kg
Number of subjects: 90
Study 10072029 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 0.4 mg/kg
Number of subjects: 90
Study 10072029 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 90
Study 7673538 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic arousal-evoking preexposure film stimulus paired with an erotic stimulus and positive-false VBV feedback
Number of subjects: 64
Study 7673538 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-control preexposure film stimulus paired with an erotic stimulus and positive-false VBV feedback
Number of subjects: 64
Study 7673538 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic arousal-evoking preexposure film stimulus paired with an erotic stimulus and no feedback
Number of subjects: 64
Study 7673538 — intervention group
Group type: COMPARATOR
Intervention: Neutral-control preexposure film stimulus paired with an erotic stimulus and no feedback
Number of subjects: 64
Study 2174653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 100
Study 2174653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine with adrenaline
Number of subjects: 100
Study 2174653 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted lignocaine solutions (1% lignocaine + 1 ml 8.4% sodium bicarbonate)
Number of subjects: 100
Study 2174653 — intervention group
Group type: COMPARATOR
Intervention: plain lignocaine
Number of subjects: 100
Study 2174653 — intervention group
Group type: COMPARATOR
Intervention: lignocaine with adrenaline
Number of subjects: 100
Study 6995193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnidazole (2 g single dose)
Number of subjects: 77
Study 6995193 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole (2 g single dose)
Number of subjects: 77
Study 29450747 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve fermented milk (BFM) - 10 billion bacteria and Lactobacillus acidophilus - 1 billion bacteria, administered one pack per day for 48 weeks
Number of subjects: 195
Study 29450747 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered one pack per day for 48 weeks
Number of subjects: 195
Study 27397588 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus acetylsalicylic acid (ASA)
Number of subjects: 0
Study 27397588 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 0
Study 25041994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) treatment, treatment arm 2
Number of subjects: 745
Study 25041994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) treatment, treatment arm 1
Number of subjects: 745
Study 25041994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) treatment, treatment arm 3
Number of subjects: 745
Study 22841431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomade-coated sutures (iodoform + calendula)
Number of subjects: 40
Study 22841431 — intervention group
Group type: COMPARATOR
Intervention: Uncoated sutures
Number of subjects: 40
Study 19952006 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution (STD-R) <50%
Number of subjects: 4729
Study 19952006 — intervention group
Group type: COMPARATOR
Intervention: ST-segment resolution (STD-R) >=50%
Number of subjects: 4729
Study 20633465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra sinica (pseudo-ephedrine 31.52 mg)
Number of subjects: 125
Study 20633465 — intervention group
Group type: EXPERIMENTAL
Intervention: Evodia rutaecarpa (evodiamine 6.75 mg, rutaecarpine 0.66 mg)
Number of subjects: 125
Study 20633465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16846413 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow technique (ST) with normothermic cardiopulmonary bypass
Number of subjects: 249
Study 16846413 — intervention group
Group type: COMPARATOR
Intervention: Iced slush with mild hypothermic cardiopulmonary bypass
Number of subjects: 249
Study 14693299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 215
Study 14693299 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 215
Study 10574639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activated protein C resistance
Number of subjects: 56
Study 10574639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant positivity
Number of subjects: 56
Study 10574639 — intervention group
Group type: COMPARATOR
Intervention: Reference group (without recurrent abortions)
Number of subjects: 56
Study 8917240 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 10
Study 8917240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 10
Study 1953322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ga‐As + He‐Ne laser treatment
Number of subjects: 58
Study 1953322 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 6958478 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms twice daily
Number of subjects: 30
Study 6958478 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 100 micrograms four times daily
Number of subjects: 30
Study 4032328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 4032328 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0
Study 4032328 — intervention group
Group type: COMPARATOR
Intervention: Listening to a story
Number of subjects: 0
Study 4032328 — intervention group
Group type: COMPARATOR
Intervention: Division of attention
Number of subjects: 0
Study 31861349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-catechin group (three daily doses of 57 mg catechins and 100 mg xanthan gum)
Number of subjects: 270
Study 31861349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-catechin group (one daily dose of 57 mg catechins and 100 mg xanthan gum)
Number of subjects: 270
Study 31861349 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0 mg catechins and 100 mg xanthan gum)
Number of subjects: 270
Study 29903459 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection adductor canal block (SACB) with 20 mL of 0.25% bupivacaine, 1.67 mcg/mL of clonidine, 2 mg of dexamethasone, 150 mcg of buprenorphine, and 2.5 mcg/mL of epinephrine
Number of subjects: 60
Study 29903459 — intervention group
Group type: COMPARATOR
Intervention: Continuous adductor canal blockade (CACB) with 20 mL of 0.25% bupivacaine and 2.5 mcg/mL of epinephrine followed by an 8 mL/h infusion of 0.125% bupivacaine
Number of subjects: 60
Study 29903459 — intervention group
Group type: EXPERIMENTAL
Intervention: SACB
Number of subjects: 60
Study 29903459 — intervention group
Group type: COMPARATOR
Intervention: CACB
Number of subjects: 60
Study 27124028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5-1.0 vol%) during CPB
Number of subjects: 153
Study 27124028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthetics alone (control group)
Number of subjects: 153
Study 25431346 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care augmented by virtual house calls with a Parkinson disease specialist
Number of subjects: 200
Study 25431346 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the community
Number of subjects: 200
Study 22218831 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant bundle preservation technique (R)
Number of subjects: 136
Study 22218831 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique (S)
Number of subjects: 136
Study 19890343 — intervention group
Group type: EXPERIMENTAL
Intervention: No-Sting skin protectant
Number of subjects: 69
Study 19890343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 69
Study 18831897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg once daily)
Number of subjects: 53
Study 18831897 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (90 mg twice daily)
Number of subjects: 53
Study 18831897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 53
Study 16212579 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-menstrual period
Number of subjects: 20
Study 16212579 — intervention group
Group type: COMPARATOR
Intervention: Post-menstrual period
Number of subjects: 20
Study 12171509 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 10085835 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous injection
Number of subjects: 46
Study 10085835 — intervention group
Group type: COMPARATOR
Intervention: Sequential injection
Number of subjects: 46
Study 7486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Video imaging presentation
Number of subjects: 74
Study 7486240 — intervention group
Group type: COMPARATOR
Intervention: Standard case presentation (CP)
Number of subjects: 74
Study 2261966 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 micrograms.day‐1 beclomethasone dipropionate (BDP)
Number of subjects: 12
Study 2261966 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg.day‐1 oral prednisone (PRD)
Number of subjects: 12
Study 7376025 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroesophageal injection sclerotherapy using a modified, rigid Negus oesophagoscope under general anaesthesia
Number of subjects: 0
Study 7376025 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study 7376025 — intervention group
Group type: COMPARATOR
Intervention: Newer forms of shunts such as the Warren shunt
Number of subjects: 0
Study 7376025 — intervention group
Group type: COMPARATOR
Intervention: Repeated sclerotherapy
Number of subjects: 0
Study 7376025 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pitressin
Number of subjects: 0
Study 7376025 — intervention group
Group type: COMPARATOR
Intervention: Sengstaken tube
Number of subjects: 0
Study 30988483 — intervention group
Group type: EXPERIMENTAL
Intervention: Information nudge about eligibility for fee waiver
Number of subjects: 933
Study 30988483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information nudge)
Number of subjects: 933
Study 29889868 — intervention group
Group type: EXPERIMENTAL
Intervention: High salience (pudding) ergogenic placebo supplement
Number of subjects: 34
Study 29889868 — intervention group
Group type: COMPARATOR
Intervention: Low salience (capsules) ergogenic placebo supplement
Number of subjects: 34
Study 29889868 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 34
Study 27151015 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell infusion
Number of subjects: 60
Study 27151015 — intervention group
Group type: COMPARATOR
Intervention: VAD chemotherapy
Number of subjects: 60